The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis

CONCLUSIONS: Anifrolumab 300 mg showed a favourable benefit-risk profile for the long-term treatment of adult patients with moderate to severe SLE from Japan, with safety, tolerability, and efficacy profiles consistent with the overall population.PMID:37706527 | DOI:10.1093/mr/road092

https://pubmed.ncbi.nlm.nih.gov/37706527/?utm_source=no_user_agent&utm_medium=rs...

Source: Herpes - September 14, 2023 Category: Infectious Diseases Authors: Yoshiya Tanaka Tatsuya Atsumi Masato Okada Tomoya Miyamura Tomonori Ishii Susumu Nishiyama Ryutaro Matsumura Atsushi Kawakami Nobuya Hayashi Gabriel Abreu Sule Yavuz Catharina Lindholm Hussein Al-Mossawi Tsutomu Takeuchi Source Type: research